Epizyme, Inc. (NASDAQ:EPZM) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Several other equities analysts have also weighed in on the stock. Cann restated a “buy” rating and set a $26.00 price target on shares of Epizyme in a research report on Tuesday, April 25th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, May 16th. Oppenheimer Holdings, Inc. set a $26.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research report on Monday, June 5th. Royal Bank Of Canada set a $20.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research report on Monday, June 12th. Finally, ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. Epizyme currently has an average rating of “Buy” and a consensus price target of $23.75.

Shares of Epizyme (EPZM) traded up 0.38% during trading on Wednesday, reaching $13.35. 308,903 shares of the company’s stock were exchanged. The stock’s market cap is $779.08 million. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.50. The stock’s 50 day moving average price is $13.88 and its 200-day moving average price is $14.26.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 55.41%. On average, equities research analysts forecast that Epizyme will post ($2.42) EPS for the current year.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/23/epizyme-inc-nasdaqepzm-downgraded-by-bidaskclub.html.

In other news, CFO Andrew E. Singer sold 3,024 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the transaction, the chief financial officer now directly owns 40,529 shares in the company, valued at $628,199.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $16.11, for a total transaction of $241,650.00. Following the completion of the transaction, the insider now owns 22,228 shares of the company’s stock, valued at $358,093.08. The disclosure for this sale can be found here. Insiders sold 40,524 shares of company stock valued at $632,397 over the last 90 days. 25.20% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its position in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. purchased a new position in Epizyme during the first quarter worth approximately $175,000. Bank of America Corp DE raised its position in Epizyme by 45.4% in the first quarter. Bank of America Corp DE now owns 14,561 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 4,544 shares during the period. Russell Investments Group Ltd. purchased a new position in Epizyme during the fourth quarter worth approximately $351,000. Finally, Metropolitan Life Insurance Co. NY raised its position in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares during the period. Institutional investors own 81.63% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.